



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

*me*

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/740,256	12/18/2003	James E. Dahlberg	FORS-08497	1902
72960	7590	11/07/2007		
Casimir Jones, S.C. 440 Science Drive Suite 203 Madison, WI 53711			EXAMINER BABIC, CHRISTOPHER M	
			ART UNIT 1637	PAPER NUMBER
			MAIL DATE 11/07/2007	DELIVERY MODE PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

## Office Action Summary

Application No.

10/740,256

Applicant(s)

DAHLBERG ET AL.

Examiner

Christopher M. Babic

Art Unit

1637

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 16 July 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 32-34, 36 and 39-82 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 32-34, 36, and 39-82 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_.
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_.
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_.

## **DETAILED ACTION**

### ***Status of the Claims***

Claim(s) 32-34, 36, and 39-82 are pending. The following Office Action is in response to Applicant's response dated July 16, 2007.

### ***Withdrawn Claim Rejections - 35 USC § 112 - 2nd Paragraph***

The previous rejection of claim(s) 32-34, 36, and 39-82 has been withdrawn in view of Applicant's amendment.

### ***New Grounds Claim Rejections - 35 USC § 112 - 2nd Paragraph***

The following new grounds of rejection are made in view of Applicant's amendments.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

**Claim(s) 32-34, 36, and 39-82 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.**

Claim 32 recites the limitation --said probe-- in step (b). There is insufficient antecedent basis for this limitation in the claim. Since step (a) refers to --said unlabeled probe--, it is unclear what probe the above limitation references.

***Withdrawn Claim Rejections - 35 USC § 103***

The rejection of claim(s) 32, 33, 47-52, 54, 57, 58, 60, 62, 71-76, and 78 Lizardi in view of Lau has been withdrawn in view of Applicant's amendment.

The rejection of claim(s) 32, 33, 39, 40, 48-52, 54, and 81 Lane in view of Lau has been withdrawn in view of Applicant's amendment.

***New Grounds of Claim Rejections - 35 USC § 103***

The following new grounds of rejections are made in view of Applicant's amendment.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

**1. Claim(s) 32, 34, 35, 37-41, 48-54, 60, 61, 63-65, 72-74, 76, 77, 81, and 82 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ledford et al. ("A multi-site study for detection of the factor V (Leiden) mutation from genomic DNA using a homogeneous invader microtiter plate fluorescence resonance energy**

**transfer (FRET) assay" J Mol Diagn. 2000 May;2(2):97-104) in view of Lane et al. (U.S. 5,770,365), and in view of Lau et al. ("An Abundant Class of Tiny RNAs with Probable Regulatory Roles in *Caenorhabditis elegans*. Science. 26 October 2001. Vol. 294: Pages 858-862).**

With regard to claim(s) 32 and 34, it is first submitted that steps a-d of the claimed invention encompass an assay, which was known at the time of invention as an Invader Assay, further comprising the use of a probe that when hybridized to the target nucleic acid forms a duplex secondary structure. Ledford teaches a homogeneous Invader microtitre plate FRET assay (abstract; fig. 1; pg. 100, Invader Assay, for example). Specifically, Ledford teaches a method comprising: a) contacting a target nucleic acids with unlabeled probes forming a detection structure (fig. 1, Invader Oligonucleotide, WT Probe, invasive cleavage structure, for example); b) reacting the detection structure with nuclease that cleaves the detection structure (fig.1, released flap; pg. 98-99, col. 1, Cleavase, for example); c) dissociating the target nucleic acid from the unlabeled probes (pg. 99, col. 1, probe turnover, for example); and d) detecting modified detection structure (fig.1, FRET detection of released flap; pg. 98-99, col. 1, FRET, for example).

With regard to claim(s) 39-41, Ledford teaches FRET detection (fig.1, FRET detection of released flap; pg. 98-99, col. 1, FRET, for example).

With regard to claim(s) 48 and 49, Ledford teaches detection of a mutation, i.e. specific type of nucleic acid (abstract; fig. 2, Leiden mutation, for example).

Art Unit: 1637

With regard to claim(s) 50, Ledford teaches a cell lysate (pg. 99, col. 2, sample prep., for example).

With regard to claim(s) 52 and 53, Ledford teaches detection of a mutation, i.e. specific type of nucleic acid within a plurality of different nucleic acids (abstract; fig. 2, Leiden mutation, for example).

With regard to claim(s) 32, 60, and 61, refer to the rejection of claim(s) 1 above.

With regard to claim(s) 63-65, refer to the rejection of claim(s) 39-41 above.

With regard to claim(s) 72 and 73, refer to the rejection of claim(s) 48 and 49 above.

With regard to claim(s) 74, refer to the rejection of claim(s) 50 above.

With regard to claim(s) 76 and 77, refer to the rejection of claim(s) 52 and 53 above.

With regard to claim(s) 81 and 82, Ledford teaches two distinct probes (fig. 1, Invader Oligonucleotide, WT Probe, invasive cleavage structure, for example).

With regard to the above claims, Ledford does not expressly teach the use of a probe that when hybridized to the target nucleic acid forms a duplex secondary structure, or the detection of microRNA.

With regard to the use of probes having secondary structure, Lane provides a supportive disclosure that teaches oligonucleotide probes having a secondary structure wherein the duplex and target regions are within one nucleotide of each other (col. 1-3, summary; col.7, lines 5-25; col. 8, lines 15-30; fig. 1, sections A-D, box 30, for example). Lane expressly teaches that the duplex region of the probe stabilizes, entropically, that -

specific region of the capture moiety and thereby favours formation of a target:probe duplex (col. 7, lines 30-40, for example).

With regard to the detection of microRNA and claim(s) 51, 54, 75, and 78, Lau provides a supporting disclosure that teaches two types of short RNAs, both about 21 to 25 nucleotides (21-25 nt) in length (lin-4 and let-7) (i.e. microRNA (miRNA)) (abstract; table 1, for example), an obvious structurally equivalent species of the genus molecule RNA. Lau further teaches the detection of miRNAs (fig. 3, for example) as well as the motivation to study these molecules, as their abundance implies that they function in a variety of regulatory pathways.

Thus, it would have been *prima facie obvious* to a skilled artisan at the time of invention to incorporate probes comprising secondary structure (i.e. hairpin structures) into the general, well known, Invader Assay as demonstrated by Ledford since Lane suggests such a modification to stabilize and enhance formation of target duplex formation. In other words, the claimed invention would have been obvious because Lane made the designing of probes with secondary structure part of the ordinary capabilities of skilled artisans. A skilled artisan would have been capable of applying this known method of enhancement, i.e. favoring a target:probe formation, to a probe based assay in a predictable manner.

Furthermore, it would have been *prima facie obvious* to a skilled artisan to apply the RNA detection methods of Lizardi to microRNA, an obvious structurally equivalent species of the genus molecule RNA since Lau suggests the detection and further study of these molecules because their abundance implies that they function in a variety of

Art Unit: 1637

regulatory pathways. Furthermore, given the small structure of microRNA, a skilled artisan would have been motivated to apply techniques that would favor formation of target:probe formation given the smaller target binding sequence.

Lastly, not only were all the modifications well within the capability of a skilled artisan at the time of invention, each would have led to a predictably functional process.

**2. Claim(s) 33, 36, 44-47, 58, 59, 62, and 68-71 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ledford et al. ("A multi-site study for detection of the factor V (Leiden) mutation from genomic DNA using a homogeneous invader microtiter plate fluorescence resonance energy transfer (FRET) assay" J Mol Diagn. 2000 May;2(2):97-104) in view of Lane et al. (U.S. 5,770,365), and in view of Lau et al. ("An Abundant Class of Tiny RNAs with Probable Regulatory Roles in *Caenorhabditis elegans*. Science. 26 October 2001. Vol. 294: Pages 858-862) as applied to claim(s) 32 and 57, and in further view of Morris et al. ("Rapid reverse transcription-PCR detection of hepatitis C virus RNA in serum by using the TaqMan fluorogenic detection system J Clin Microbiol. 1996 Dec;34(12):2933-6).**

The teachings of the previously applied references have been outlined in above rejections. The above references do not expressly teach a detection procedure that includes the polymerase chain reaction (PCR), more specifically, a PCR that utilizes a fluorescent probe configured for FRET detection.



Morris provides a supporting disclosure that teaches TaqMan RT-PCR encompassing the limitations set forth in the above claims (fig. 1; pg. 2934, Materials and Methods, RT-PCR, for example). Furthermore, they teach that in the TaqMan assay post amplification manipulations are reduced therefore offering significant time savings.

Thus, it would have been *prima facie obvious* to a skilled artisan at the time of invention to incorporate TaqMan PCR detection into the general, well known, Invader Assay as demonstrated by Ledford since Morris suggests such a modification to allow homogeneous detection thereby reducing experimental time. In other words, the claimed invention would have been obvious because Lane made the TaqMan PCR detection assay part of the ordinary capabilities of skilled artisans. A skilled artisan would have been capable of applying this known method of enhancement, i.e. reducing experimental time, to a probe based assay in a predictable manner.

Lastly, not only were all the modifications well within the capability of a skilled artisan at the time of invention, each would have led to a predictably functional process.

**3. Claim(s) 42, 43, 66, and 67 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ledford et al. ("A multi-site study for detection of the factor V (Leiden) mutation from genomic DNA using a homogeneous invader microtiter plate fluorescence resonance energy transfer (FRET) assay" J Mol Diagn. 2000 May;2(2):97-104) in view of Lane et al. (U.S. 5,770,365), and in view of Lau et al. ("An Abundant Class of Tiny RNAs with Probable Regulatory Roles in**

***Caenorhabditis elegans*. Science. 26 October 2001. Vol. 294: Pages 858-862) as applied to claim(s) 32 and 57, and in further view of Marras et al. "Multiplex detection of single-nucleotide variations using molecular beacons" Genet Anal. 1999 Feb;14(5-6):151-6).**

The teachings of the previously applied references have been outlined in above rejections. The above references do not expressly teach detection procedures that include the use of probes that form different conformations upon hybridization or the detection of polymorphisms.

Marras provides a supporting disclosure that teaches detection of single-nucleotide variants (pg. 154, col. 2, for example) through the incorporation of FRET enabled molecular beacons in a homogeneous assay (fig. 1; pg. 152, col. 2, for example). Furthermore, Marras teaches that molecular beacons are uniquely suited for the detection of single-nucleotide variants because they bind their targets with higher specificity than conventional oligonucleotide probes (pg. 152, col. 1, for example).

Thus, it would have been *prima facie obvious* to a skilled artisan at the time of invention to incorporate FRET enabled molecular beacons into the general, well known, Invader Assay as demonstrated by Ledford since Marras suggests such a modification to allow homogeneous detection. Moreover, the probes bind their targets with higher specificity than conventional oligonucleotide probes. In other words, the claimed invention would have been obvious because Marras made the use of molecular beacons part of the ordinary capabilities of skilled artisans. A skilled artisan would have

been capable of applying this known method of enhancement, i.e. homogeneous detection, to a probe based assay in a predictable manner.

Lastly, not only were all the modifications well within the capability of a skilled artisan at the time of invention, each would have led to a predictably functional process.

**4. Claim(s) 55, 56, 79, and 80 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ledford et al. ("A multi-site study for detection of the factor V (Leiden) mutation from genomic DNA using a homogeneous invader microtiter plate fluorescence resonance energy transfer (FRET) assay" J Mol Diagn. 2000 May;2(2):97-104) in view of Lane et al. (U.S. 5,770,365), and in view of Lau et al. ("An Abundant Class of Tiny RNAs with Probable Regulatory Roles in *Caenorhabditis elegans*. Science. 26 October 2001. Vol. 294: Pages 858-862) as applied to claim(s) 32 and 57, and in further view of Hyldig-Nielsen et al. (U.S. 5,985,563).**

The teachings of the previously applied references have been outlined in above rejections. The above references do not expressly teach the use of peptide nucleic acids (PNAs).

Hyldig-Nielsen provides a supporting disclosure that teaches an assay using PNA probes (col. 17, lines 30-45; col. 19,20, ex. 1, for example). Hyldig-Nielsen further teaches that PNAs have a higher thermal instability of mismatching bases whereby

PNAs exhibit a greater specificity for their complementary nucleic acids than traditionally used nucleic acid probes (col. 2, lines 40-55).

Thus, it would have been *prima facie obvious* to a skilled artisan at the time of invention to incorporate PNA probes into the general, well known, Invader Assay as demonstrated by Ledford since Hyldig-Nielsen suggests such a modification to provide for probes with greater specificity. In other words, the claimed invention would have been obvious because Hyldig-Nielsen made the use of PNA probes part of the ordinary capabilities of skilled artisans. A skilled artisan would have been capable of applying this known method of enhancement, i.e. probes with greater specificity, to a probe based assay in a predictable manner.

Lastly, not only were all the modifications well within the capability of a skilled artisan at the time of invention, each would have led to a predictably functional process.

### ***Conclusion***

**Claim(s) 32-34, 36, and 39-82 are rejected. No claims are allowed.**

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher M. Babic whose telephone number is 571-272-8507. The examiner can normally be reached on Monday-Friday 7:00AM to 4:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.


Art Unit: 1637

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



11/5/07

Christopher M. Babic  
Patent Examiner  
Art Unit 1637  
Technology Center 1600



KENNETH R. HORLICK, PH.D  
PRIMARY EXAMINER

11/6/07